Novartis's Sandoz to Commercialize Autoimmune Disorders Antibody in Europe, North America
11 Setembro 2023 - 03:02AM
Dow Jones News
By Mauro Orru
Novartis's generics-and-biosimilars division Sandoz entered into
an agreement with Samsung Bioepis to commercialize in Europe and
North America an antibody medication for the treatment of
autoimmune disorders such as Crohn's disease, plaque psoriasis,
psoriatic arthritis, and ulcerative colitis.
The company said Monday that the development and
commercialization agreement handed Sandoz exclusive rights to
commercialize biosimilar SB17 ustekinumab in the U.S., Canada, the
European Economic Area, Switzerland, and the U.K. Sandoz said other
specific terms of the agreement are confidential.
"It will further strengthen our immunology patient offering and
means we now have five potential high-value upcoming biosimilar
launches over the next few years," said Sandoz Chief Executive
Richard Saynor.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
September 11, 2023 01:47 ET (05:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Nov 2023 até Dez 2023
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2022 até Dez 2023
